Market Cap | 107M | P/E | - | EPS this Y | 49.40% | Ern Qtrly Grth | - |
Income | -52.16M | Forward P/E | 9.60 | EPS next Y | -24.40% | 50D Avg Chg | 20.00% |
Sales | 1.46M | PEG | 0.19 | EPS past 5Y | - | 200D Avg Chg | 18.00% |
Dividend | N/A | Price/Book | 0.99 | EPS next 5Y | -76.70% | 52W High Chg | -15.00% |
Recommedations | 1.70 | Quick Ratio | 27.62 | Shares Outstanding | 67.43M | 52W Low Chg | 102.00% |
Insider Own | 20.43% | ROA | -12.03% | Shares Float | 43.36M | Beta | 1.45 |
Inst Own | 57.90% | ROE | -23.20% | Shares Shorted/Prior | 7.14M/6.95M | Price | 0.38 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 278,531 | Target Price | 22.63 |
Oper. Margin | -2,711.60% | Earnings Date | - | Volume | 145,041 | Change | 0.00% |
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Wedbush | Outperform | Oct 1, 24 |
Truist Securities | Buy | Sep 25, 24 |
Cantor Fitzgerald | Overweight | Sep 10, 24 |
Cantor Fitzgerald | Overweight | Sep 9, 24 |
Cantor Fitzgerald | Overweight | Sep 6, 24 |
Cantor Fitzgerald | Overweight | Sep 3, 24 |
RBC Capital | Outperform | Aug 16, 24 |
Oppenheimer | Outperform | Aug 13, 24 |
B of A Securities | Buy | Jul 25, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Williamson Robert F III | Director Director | Jan 30 | Buy | 0.71 | 127,206 | 90,316 | 338,761 | 02/01/24 |
Williamson Robert F III | Director Director | Jan 26 | Buy | 0.6 | 135,879 | 81,527 | 211,555 | 01/30/24 |
Puhlmann Markus | Chief Medical Office.. Chief Medical Officer | Jan 24 | Buy | 0.49960 | 280,000 | 139,888 | 1,375,425 | 01/26/24 |
Williamson Robert F III | Director Director | Jan 24 | Buy | 0.49 | 51,996 | 25,478 | 75,676 | 01/26/24 |
Williamson Robert F III | Director Director | Dec 21 | Buy | 0.3283 | 3,663 | 1,203 | 3,663 | 12/26/23 |
Hunt Jonathan Robert | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Buy | 0.2587 | 125,000 | 32,338 | 316,710 | 12/19/23 |
Williamson Robert F III | Director Director | Dec 18 | Buy | 0.29 | 23,680 | 6,867 | 23,680 | 12/19/23 |
Puhlmann Markus | Chief Medical Office.. Chief Medical Officer | Dec 15 | Buy | 0.29 | 595,425 | 172,673 | 1,095,425 | 12/19/23 |
Woods Lori A | Director Director | Apr 13 | Option | 0.61 | 187,500 | 114,375 | 1,334,538 | 04/19/23 |
Hunt Jonathan Robert | Chief Financial Offi.. Chief Financial Officer | Dec 01 | Buy | 0.38 | 85,404 | 32,454 | 191,710 | 12/05/22 |
Streeter Jennifer | COO & VP of HR COO & VP of HR | Aug 18 | Option | 0.43 | 50,000 | 21,500 | 87,940 | 08/19/22 |
Streeter Jennifer | COO & VP of HR COO & VP of HR | Aug 05 | Option | 0.33 | 22,500 | 7,425 | 27,940 | 08/10/22 |
Austin Mark John | VP Finance/Prin Fin&.. VP Finance/Prin Fin&Acct Offic | Jun 08 | Buy | 0.29 | 18,800 | 5,452 | 54,030 | 06/09/22 |
Woods Lori A | CEO CEO | Jun 07 | Buy | 0.29640 | 75,000 | 22,230 | 1,047,038 | 06/09/22 |
Hunt Jonathan Robert | Chief Financial Offi.. Chief Financial Officer | Jun 07 | Buy | 0.28 | 39,000 | 10,920 | 106,306 | 06/09/22 |
Woods Lori A | CEO CEO | Nov 23 | Option | 0.45 | 125,000 | 56,250 | 972,038 | 11/24/21 |